Clinical Trials
169 trialsPazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
STARTRK-2
Hoffmann-La Roche
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Institutes of Health Clinical Center (CC)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
PLANE-PC
University of Michigan Rogel Cancer Center
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors
University of Alberta
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
ALPHAMEDIX02
Orano Med LLC
DeLLphi-307
Amgen
ANTARES
Instituto do Cancer do Estado de São Paulo
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
I-MAT
Melanoma and Skin Cancer Trials Limited
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
M.D. Anderson Cancer Center
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
SUR-CAN
Centre Oscar Lambret
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
University of California, San Francisco
Entinostat Neuroendocrine (NE) Tumor
Columbia University
MOST-CIRCUIT
Olivia Newton-John Cancer Research Institute
TENET
Tata Memorial Hospital
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
University of Utah
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
ArTisaN
Imperial College London
NELMAS
Imperial College London
PELICAN
Imperial College London
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs)
Washington University School of Medicine
CapTemY90
Abramson Cancer Center at Penn Medicine
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors
University of Alberta
Patients With High-grade Pancreatic Neuroendocrine Tumors
National Cancer Center, Korea
KEYNOTE 158
Merck Sharp & Dohme LLC
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases
University of California, San Francisco
STOPNET
Australasian Gastro-Intestinal Trials Group
Open-Label Surufatinib in European Patients With NET
Hutchmed
TALENT
Grupo Espanol de Tumores Neuroendocrinos
LUTARTERIAL
University Hospital, Bordeaux
LUMOD-ID
University of Iowa
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours
Azienda USL Reggio Emilia - IRCCS
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Erasmus Medical Center
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
NESSIE
Peking University
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Clarity Pharmaceuticals Ltd
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors
Latin American Cooperative Oncology Group
Cabozantinib and Nivolumab for Carcinoid Tumors
Dana-Farber Cancer Institute